Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy
about
Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice.Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.Alternative Splicing in the Hippo Pathway-Implications for Disease and Potential Therapeutic Targets.Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
P2860
Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
name
Development of an orally avail ...... in Duchenne muscular dystrophy
@ast
Development of an orally avail ...... in Duchenne muscular dystrophy
@en
type
label
Development of an orally avail ...... in Duchenne muscular dystrophy
@ast
Development of an orally avail ...... in Duchenne muscular dystrophy
@en
prefLabel
Development of an orally avail ...... in Duchenne muscular dystrophy
@ast
Development of an orally avail ...... in Duchenne muscular dystrophy
@en
P2093
P2860
P50
P356
P1433
P1476
Development of an orally avail ...... in Duchenne muscular dystrophy
@en
P2093
Atsushi Nishida
Kensuke Ninomiya
Masafumi Matsuo
Masatoshi Hagiwara
Masayasu Toyomoto
Naohiro Hashimoto
Yuka Koike
Yukiko Okuno
Yukiya Sako
P2860
P2888
P356
10.1038/SREP46126
P407
P577
2017-05-30T00:00:00Z
P6179
1085704757